FCGR3A and APCS

Number of citations of the paper that reports this interaction (PubMedID 11359830)
48

Data Source:
HPRD (in vitro)

		FCGR3A	APCS
Description		Fc fragment of IgG receptor IIIa	amyloid P component, serum
Image
GO Annotations	Cellular Component	Plasma Membrane External Side Of Plasma Membrane Integral Component Of Membrane Extracellular Exosome	Extracellular Region Extracellular Space Nucleus Collagen-containing Extracellular Matrix Extracellular Exosome Blood Microparticle
	Molecular Function	IgG Binding	Complement Component C1q Binding Calcium Ion Binding Protein Binding Low-density Lipoprotein Particle Binding Carbohydrate Binding Identical Protein Binding Virion Binding Unfolded Protein Binding
	Biological Process	Immune Response Fc-gamma Receptor Signaling Pathway Involved In Phagocytosis Regulation Of Immune Response	Negative Regulation Of Acute Inflammatory Response Protein Folding Acute-phase Response Complement Activation, Classical Pathway Cellular Protein Metabolic Process Negative Regulation By Host Of Viral Process Negative Regulation By Host Of Viral Exo-alpha-sialidase Activity Negative Regulation By Host Of Viral Glycoprotein Metabolic Process Innate Immune Response Negative Regulation Of Monocyte Differentiation Negative Regulation Of Viral Entry Into Host Cell Negative Regulation Of Viral Process Chaperone-mediated Protein Complex Assembly Negative Regulation Of Wound Healing Negative Regulation Of Exo-alpha-sialidase Activity Negative Regulation Of Glycoprotein Metabolic Process
Pathways		Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell FCGR activation FCGR activation Regulation of actin dynamics for phagocytic cup formation Role of phospholipids in phagocytosis FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis	Amyloid fiber formation
Drugs		Cetuximab Etanercept Immune Globulin Human Adalimumab Abciximab Gemtuzumab ozogamicin Trastuzumab Rituximab Basiliximab Muromonab Ibritumomab tiuxetan Tositumomab Alemtuzumab Alefacept Efalizumab Natalizumab Palivizumab Daclizumab Bevacizumab Sarilumab Benralizumab	Zinc Methyl 4,6-O-[(1r)-1-Carboxyethylidene]-Beta-D-Galactopyranoside BIS-1,2-{[(Z)-2-CARBOXY-2-METHYL-1,3-DIOXANE]-5-YLOXYCARBAMOYL}-ETHANE BIS-1,2-{[(Z)-2CARBOXY-2-METHYL-1,3-DIOXANE]-5-YLOXYCARBONYL}-PIPERAZINE Copper
Diseases		NK cell defects, including the following disease: CD16 deficiency Systemic lupus erythematosus
GWAS		Birth weight ( 31043758) Blood protein levels ( 28240269) Functional impairment in major depressive disorder, bipolar disorder and schizophrenia ( 24039173) Inflammatory bowel disease ( 28067908 23128233) Systemic lupus erythematosus ( 28714469) Takayasu arteritis ( 30498034 23830517) Ulcerative colitis ( 28067908)	Blood protein levels ( 30072576 29875488 28240269) C-reactive protein ( 22939635)
Interacting Genes		18 interacting genes: APCS APP CD247 CD38 CD4 FCER1G FCGR1A GP6 IGHG1 LCK PRKCA PRKCI PTPRC S100A4 SHC1 SYK ZAP70 ZBTB25	17 interacting genes: C1QA C4BPA CALU COL4A1 COPS5 CRP FCGR1A FCGR2B FCGR3A FCGR3B FN1 GK GOT2 GRB2 HES1 LAMA1 TG
Entrez ID		2214	325
HPRD ID		00903	00101
Ensembl ID		ENSG00000203747	ENSG00000132703
Uniprot IDs		M9MML0 P08637	P02743 V9HWP0
PDB IDs		3AY4 3SGJ 3SGK 3WN5 5BW7 5D6D 5ML9 5MN2 5VU0 5XJE 5XJF 5YC5	1GYK 1LGN 1SAC 2A3W 2A3X 2A3Y 2W08 3D5O 3KQR 4AVS 4AVT 4AVV 4AYU
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?